# US 2012/0252802 A1 · (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252802 A1
- Document ID: US20120252802A1
- Status: Published application
- Kind: A1
- Application number: 13/431,716
- Filed: 2012-03-27
- Published: 2012-10-04
- Earliest claimed: 2011-03-28
- Assignees: Pathway Therapeutics Inc.
- Inventors: S. David Brown; David J. Matthews
- Web page: https://patentgrep.com/patent/US20120252802A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/10: for impotence
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/18: for HIV
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.

## Claims

### Claim 1

A compound of Formula I:
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where RX is hydrogen or C1-6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c; wherein each R1a, R1b, R1c, and R1d is independently (i) hydrogen; (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) R1b and R1c together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrogen or C1-6 alkyl; or R3 and R4 are linked together to form a bond, C1-6 alkylene, C1-6 heteroalkylene, C2-6 alkenylene, or C2-6 heteroalkenylene;
R5a is (a) hydrogen or halo; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c;
R5b is (a) halo; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c;
R5c is —(CR5fR5g)n—(C6-14 aryl) or —(CR5fR5g)n-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c;
R5f and R5g are each independently (a) hydrogen or halo; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c; or —S(O)2NR1bR1c; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3-10 cycloalkyl or heterocyclyl;
R6 is hydrogen, C1-6 alkyl, —S—C1-6 alkyl, —S(O)—C1-6 alkyl, or —SO2—C1-6 alkyl;
m is 0 or 1; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl in R1, R2, R3, R4, R6, RX, R1a, R1b, R1c, R1d, R5a, R5b, R5c, R5d, R5e, R5f, and R5g is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each substituent Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Qa; and (c) —C(O)Ra, —C(O)ORa, —C(O)NRbRc, —C(NRa)NRbRc, —ORa, —OC(O)Ra, —OC(O)ORa, —OC(O)NRbRc, —OC(═NRa)NRbRc, —OS(O)Ra, —OS(O)2Ra, —OS(O)NRbRc, —OS(O)2NRbRc, —NRbRc, —NRaC(O)Rd, —NRaC(O)ORd, —NRaC(O)NRbRc, —NRaC(═NRd)NRbRc, —NRaS(O)Rd, —NRaS(O)2Rd, —NRaS(O)NRbRc, —NRaS(O)2NRbRc, —SRa, —S(O)Ra, —S(O)2Ra, —S(O)NRbRc, and —S(O)2NRbRc, wherein each Ra, R1', Rc, and Rd is independently (i) hydrogen; (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Qa;
wherein each Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Re, —C(O)ORe, —C(O)NRfRg, —C(NRe)NRfRg, —ORe, —OC(O)Re, —OC(O)ORe, —OC(O)NRfRg, —OC(═NRe)NRfRg, —OS(O)Re, —OS(O)2Re, —OS(O)NRfRg, —OS(O)2NRfRg, —NRfRg, —NReC(O)Rh, —NReC(O)ORh, —NReC(O)NRfRg, —NReC(═NRh)NRfRg, —NReS(O)Rh, —NReS(O)2Rh, —NReS(O)NRfRg, —NReS(O)2NRfRg, —SRe, —S(O)Re, —S(O)2Re, —S(O)NRfRg, and —S(O)2NRfRg; wherein each Re, Rf, Rg, and Rh is independently (i) hydrogen; (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rf and Rg together with the N atom to which they are attached form heterocyclyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is not 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-N-(2-phenyl-2-(pyrrolidin-1-yl)ethyl)-1,3,5-triazin-2-amine or 6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(1-(4-((R)-3-(methoxymethyl)morpholino)phenyl)ethyl)-2-morpholinopyrimidin-4-amine.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R5b is (a) halo; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, or heteroaryl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —S(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R5a and R5b are each independently (a) halo; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R5a and R5b are each methyl, optionally substituted with one or more halo.

### Claim 6 (depends on 1)

The compound of claim 1, wherein n is 1.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R5f and R5g are each hydrogen.

### Claim 8 (depends on 1)

The compound of claim 1, wherein n is 0.

### Claim 9 (depends on 1)

The compound of claim 1, wherein m is 0.

### Claim 10 (depends on 1)

The compound of claim 1, having the structure of Formula Ia:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 11 (depends on 1)

The compound of claim 1, having the structure of Formula Ib:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 12 (depends on 1)

The compound of claim 1, having the structure of Formula II:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 13 (depends on 12)

The compound of claim 12, having the structure of Formula IIa:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 14 (depends on 12)

The compound of claim 12, having the structure of Formula lib:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R5c is C6-14 aryl, optionally substituted with one or more substituents Q.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R5c is phenyl, optionally substituted with one or more substituents Q.

### Claim 17 (depends on 15)

The compound of claim 15, wherein R5c is naphthyl, optionally substituted with one or more substituents Q.

### Claim 18 (depends on 1)

The compound of claim 1, wherein R5c is —(CR5fR5g)n—(C6-14 aryl), wherein the aryl is optionally substituted with one or more substituents Q.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R5c is —(CH2)-phenyl, wherein the phenyl is optionally substituted with one or more substituents Q.

### Claim 20 (depends on 18)

The compound of claim 18, wherein R5c is —(CH2)-naphthyl, wherein the naphthyl is optionally substituted with one or more substituents Q.

### Claim 21 (depends on 1)

The compound of claim 1, wherein R5c is heteroaryl, optionally substituted with one or more substituents Q.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R5c is monocyclic heteroaryl, optionally substituted with one or more substituents Q.

### Claim 23 (depends on 21)

The compound of claim 21, wherein R5c is 5- or 6-membered heteroaryl, optionally substituted with one or more substituents Q.

### Claim 24 (depends on 21)

The compound of claim 21, wherein R5c is bicyclic heteroaryl, optionally substituted with one or more substituents Q.

### Claim 25 (depends on 1)

The compound of claim 1, wherein R5c is —(CR5fR5g)n-heteroaryl, wherein the heteroaryl is optionally substituted with one or more substituents Q.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R5c is —(CR5fR5g)n-(monocyclic heteroaryl), wherein the heteroaryl is optionally substituted with one or more substituents Q.

### Claim 27 (depends on 25)

The compound of claim 25, wherein R5c is —(CR5fR5g)n-(5- or 6-membered heteroaryl), wherein the heteroaryl is optionally substituted with one or more substituents Q.

### Claim 28 (depends on 25)

The compound of claim 25, wherein R5c is —(CR5fR5g)n-(bicyclic heteroaryl), wherein the heteroaryl is optionally substituted with one or more substituents Q.

### Claim 29 (depends on 1)

The compound of claim 1, having the structure of Formula VII:
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
R7a, R7b, R7c, R7d, and R7e are each independently (a) hydrogen, cyano, halo, or nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c; or
two of R7a, R7b, R7c, R7d, and R7e that are adjacent to each other form C3-10 cycloalkenyl, C6-14 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q.

### Claim 30 (depends on 29)

The compound of claim 29, having the structure of Formula VIIa:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 31 (depends on 29)

The compound of claim 29, having the structure of Formula VIIb:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 32 (depends on 1)

The compound of claim 1, having the structure of Formula XI:
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
R7a, R7b, R7c, R7d, and R7e are each independently (a) hydrogen, cyano, halo, or nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(═NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c; or
two of R7a, R7b, R7c, R7d, and R7e that are adjacent to each other form C3-10 cycloalkenyl, C6-14 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q.

### Claim 33 (depends on 32)

The compound of claim 32, having the structure of Formula XIa:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 34 (depends on 32)

The compound of claim 32, having the structure of Formula XIb:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 35 (depends on 32)

The compound of claim 32, wherein R7a is hydrogen, halo, C1-6 alkyl optionally substituted with one or more substituents Q, or —OR1a.

### Claim 36 (depends on 35)

The compound of claim 35, wherein R7a is hydrogen.

### Claim 37 (depends on 35)

The compound of claim 35, wherein R7a is (a) cyano, halo, or nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, OC(NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(═NR1)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c.

### Claim 38 (depends on 35)

The compound of claim 35, wherein R7a is (i) halo; (ii) C1-6 alkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q; or (iii) —OR1a or —NR1bR1c.

### Claim 39 (depends on 32)

The compound of claim 32, wherein R7b is hydrogen, halo, C1-6 alkyl optionally substituted with one or more substituents Q, or —OR1a.

### Claim 40 (depends on 39)

The compound of claim 39, wherein R7b is hydrogen.

### Claim 41 (depends on 32)

The compound of claim 32, wherein R7a is hydrogen, halo, C1-6 alkyl optionally substituted with one or more substituents Q, or —OR1a.

### Claim 42 (depends on 41)

The compound of claim 41, wherein R7a is hydrogen, halo, or —OR1a.

### Claim 43 (depends on 41)

The compound of claim 41, wherein R7a is chloro.

### Claim 44 (depends on 41)

The compound of claim 41, wherein R7a is —O—C1-6 alkyl, optionally substituted with one or more substituents Q.

### Claim 45 (depends on 32)

The compound of claim 32, wherein R7d is hydrogen, halo, C1-6 alkyl optionally substituted with one or more substituents Q, or —OR1a.

### Claim 46 (depends on 45)

The compound of claim 45, wherein R7d is hydrogen.

### Claim 47 (depends on 32)

The compound of claim 32, wherein R7e is hydrogen, halo, C1-6 alkyl optionally substituted with one or more substituents Q, or —OR1a.

### Claim 48 (depends on 47)

The compound of claim 47, wherein R7e is hydrogen.

### Claim 49 (depends on 32)

The compound of claim 32, wherein two of R7a, R7b, R7c, R7d, and R7e that are adjacent to each other form C3-10 cycloalkenyl, C6-14 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q.

### Claim 50 (depends on 49)

The compound of claim 49, wherein R7a and R7b together with the carbon atoms to which they are attached from C6-14 aryl, optionally substituted with one or more substituents Q.

### Claim 51 (depends on 49)

The compound of claim 49, wherein R7b and R7a together with the carbon atoms to which they are attached from C6-14 aryl, optionally substituted with one or more substituents Q.

### Claim 52 (depends on 1)

The compound of claim 1, wherein R5a is hydrogen.

### Claim 53 (depends on 1)

The compound of claim 1, wherein R5a is C1-6 alkyl, optionally substituted with one or more substituents Q.

### Claim 54 (depends on 1)

The compound of claim 1, wherein R5a is hydrogen, methyl, or ethyl.

### Claim 55 (depends on 1)

The compound of claim 1, wherein R5b is C1-6 alkyl, optionally substituted with one or more substituents Q.

### Claim 56 (depends on 55)

The compound of claim 55, wherein R5b is methyl, ethyl, or propyl.

### Claim 57 (depends on 1)

The compound of claim 1, wherein R5b is —C(O)OR1a.

### Claim 58 (depends on 57)

The compound of claim 57, wherein R5b is —C(O)O—C1-6 alkyl.

### Claim 59 (depends on 57)

The compound of claim 57, wherein R5b is —C(O)OCH3.

### Claim 60 (depends on 32)

The compound of claim 32, having the structure of Formula XV:
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 61 (depends on 60)

The compound of claim 60, having the structure of Formula XVa:
or an isotopic variant thereof or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 62 (depends on 60)

The compound of claim 60, having the structure of Formula XVb:
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

### Claim 63 (depends on 60)

The compound of claim 60, wherein R5a is C1-6 alkyl, optionally substituted with one or more substituents Q.

### Claim 64 (depends on 63)

The compound of claim 63, wherein R5a is methyl.

### Claim 65 (depends on 60)

The compound of claim 60, wherein R5b is C1-6 alkyl, optionally substituted with one or more substituents Q.

### Claim 66 (depends on 65)

The compound of claim 65, wherein R5b is methyl.

### Claim 67 (depends on 60)

The compound of claim 60, wherein R5a and R5b are methyl.

### Claim 68 (depends on 60)

The compound of claim 60, wherein R7a is hydrogen, halo, C1-6 alkyl, C6-14 aryl, heteroaryl, or heterocyclyl, where the alkyl, aryl, heteroaryl, and heterocyclyl are each optionally substituted with one or more substituents Q.

### Claim 69 (depends on 68)

The compound of claim 68, wherein R7a is C6-14 aryl, optionally substituted with one or more substituents Q.

### Claim 70 (depends on 69)

The compound of claim 69, wherein R7a is phenyl, optionally substituted with one or more substituents Q.

### Claim 71 (depends on 69)

The compound of claim 69, wherein R7a is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-florophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, or 3-morpholin-4-ylmethylphenyl.

### Claim 72 (depends on 68)

The compound of claim 68, wherein R7a is heteroaryl, optionally substituted with one or more substituents Q.

### Claim 73 (depends on 72)

The compound of claim 72, wherein R7a is monocyclic heteroaryl, optionally substituted with one or more substituents Q.

### Claim 74 (depends on 72)

The compound of claim 72, wherein R7a is 5- or 6-membered heteroaryl, each optionally substituted with one or more substituents Q.

### Claim 75 (depends on 74)

The compound of claim 74, wherein R7a is imidazolyl, pyrozolyl, pyridinyl, or pyrimidinyl, each optionally substituted with one or more substituents Q.

### Claim 76 (depends on 74)

The compound of claim 74, wherein R7a is imidazol-1-yl, pyrozol-4-yl, 1-methyl-pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-1-yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl.

### Claim 77 (depends on 68)

The compound of claim 68, wherein R7a is heterocyclyl, optionally substituted with one or more substituents Q.

### Claim 78 (depends on 77)

The compound of claim 77, wherein R7a is monocyclic heterocyclyl, optionally substituted with one or more substituents Q.

### Claim 79 (depends on 77)

The compound of claim 77, wherein R7a is 5- or 6-membered heterocyclyl, each optionally substituted with one or more substituents Q.

### Claim 80 (depends on 79)

The compound of claim 79, wherein R7a is pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one or more substituents Q.

### Claim 81 (depends on 79)

The compound of claim 79, wherein R7a is pyrrolidin-3-yl, 1-methylpyrrolidin-3-yl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-ethylpiperidin-4-yl, 1-isopropylpiperidin-4-yl, 1-acetylpiperidin-4-yl, 1-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-1-yl.

### Claim 82 (depends on 60)

The compound of claim 60, wherein R7b is hydrogen, halo, or C1-6 alkyl optionally substituted with one or more substituents Q.

### Claim 83 (depends on 82)

The compound of claim 82, wherein R7b is hydrogen.

### Claim 84 (depends on 60)

The compound of claim 60, wherein R7a is hydrogen, halo, or C1-6 alkyl optionally substituted with one or more substituents Q.

### Claim 85 (depends on 84)

The compound of claim 84, wherein R7a is hydrogen.

### Claim 86 (depends on 60)

The compound of claim 60, wherein R7d is hydrogen, halo, or C1-6 alkyl optionally substituted with one or more substituents Q.

### Claim 87 (depends on 86)

The compound of claim 86, wherein R7d is hydrogen.

### Claim 88 (depends on 60)

The compound of claim 60, wherein R7e is hydrogen, halo, or C1-6 alkyl optionally substituted with one or more substituents Q.

### Claim 89 (depends on 88)

The compound of claim 88, wherein R7e is hydrogen.

### Claim 90 (depends on 60)

The compound of claim 60, wherein R7a is C6-14 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q; and R7b, R7c, R7d, and R7e are hydrogen.

### Claim 91 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen.

### Claim 92 (depends on 1)

The compound of claim 1, wherein R1 is —OR1a.

### Claim 93 (depends on 92)

The compound of claim 92, wherein R1 is —O—C1-6 alkyl.

### Claim 94 (depends on 92)

The compound of claim 92, wherein R1 is methoxy.

### Claim 95 (depends on 1)

The compound of claim 1, wherein R2 is hydrogen.

### Claim 96 (depends on 1)

The compound of claim 1, wherein R2 is NR1bR1c.

### Claim 97 (depends on 96)

The compound of claim 96, wherein R2 is amino.

### Claim 98 (depends on 1)

The compound of claim 1, wherein R3 is hydrogen.

### Claim 99 (depends on 1)

The compound of claim 1, wherein R4 is hydrogen.

### Claim 100 (depends on 1)

The compound of claim 1, wherein R6 is C1-6 alkyl, optionally substituted with one or more substituents Q.

### Claim 101 (depends on 100)

The compound of claim 100, wherein R6 is methyl, fluoromethyl, difluoromethyl, or trifluoromethyl.

### Claim 102 (depends on 100)

The compound of claim 100, wherein R6 is difluoromethyl.

### Claim 103 (depends on 1)

The compound of claim 1, wherein X is N.

### Claim 104 (depends on 1)

The compound of claim 1, wherein X is CRX.

### Claim 105 (depends on 104)

The compound of claim 104, wherein X is CH.

### Claim 106 (depends on 1)

The compound of claim 1, wherein Y is N.

### Claim 107 (depends on 1)

The compound of claim 1, wherein Y is CRX.

### Claim 108 (depends on 107)

The compound of claim 107, wherein Y is CH.

### Claim 109 (depends on 1)

The compound of claim 1, wherein Z is N.

### Claim 110 (depends on 1)

The compound of claim 1, wherein Z is CRX.

### Claim 111 (depends on 110)

The compound of claim 110, wherein Z is CH.

### Claim 112 (depends on 1)

The compound of claim 1, wherein X, Y, and Z are N.

### Claim 113 (depends on 1)

The compound of claim 1 selected from the group consisting of:
and enantiomers, mixtures of enantiomers, mixtures of two or more diastereomers, and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof.

### Claim 114 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and one or more pharmaceutically acceptable excipients.

### Claim 115 (depends on 114)

The pharmaceutical composition of claim 114, wherein the composition is formulated for single dose administration.

### Claim 116 (depends on 114)

The pharmaceutical composition of claim 114, wherein the composition is formulated as an oral, parenteral, or intravenous dosage form.

### Claim 117 (depends on 116)

The pharmaceutical composition of claim 116, wherein the composition is formulated as an oral dosage form.

### Claim 118 (depends on 117)

The pharmaceutical composition of claim 117, wherein the oral dosage form is a tablet or capsule.

### Claim 119 (depends on 114)

The pharmaceutical composition of claim 114, further comprising a second therapeutic agent.

### Claim 120 (depends on 1)

A method for the treatment, prevention, or amelioration of one or more symptoms of a PI3K-mediated disorder, disease, or condition in a subject, which comprises administering to the subject the compound of claim 1.

### Claim 121 (depends on 120)

The method of claim 120, wherein the PI3K-mediated disorder, disease, or condition is an inflammatory disease.

### Claim 122 (depends on 120)

The method of claim 120, wherein the compound or the composition is administered in combination with a second therapeutic agent.

### Claim 123 (depends on 1)

A method for modulating PI3K enzymatic activity, comprising contacting a PI3K enzyme with the compound of claim 1.

### Claim 124 (depends on 120)

The method of claim 120, wherein the PI3K is a wild type.

### Claim 125 (depends on 120)

The method of claim 120, wherein the PI3K is a PI3K variant.

### Claim 126 (depends on 120)

The method of claim 120, wherein the PI3K is a Class I PI3K.

### Claim 127 (depends on 126)

The method of claim 126, wherein the PI3K is p110γ.
